Amylyx Pharmaceuticals

Edit info

Founded: 2013

Location: Cambridge, MA

Employee range: 200 - 500

Clinical stage: COM

Therapy area: ALS

Drug types: NEU, GEN, PED, RAR

Lead product: Relyvrio (AMX0035)

Funding: $246M stock Oct 2022; $190M IPO Jan 2022; $135M C Jul 2021; $30M B Jun 2020; $5M A Aug 2016; $3M Grant Jul 2016; $1.9M Nov 2015

amylyx.com

linkedin.com

job board

Drug notes:

Also Clin2 PSP, Clin2 Wolfram syndrome, Clin2 Alzheimer's; AMX0114 Clin0 ALS, neurodegenerative diseases; undisclosed programs RD ALS, neurodegenerative diseases

About:

Amylyx is developing therapeutics for neurodegenerative disorders. A common feature of neurodegenerative diseases is neuronal death, which can be triggered when multiple stress factors are activated. Amylyx is identifying ways to preserve neurons by understanding the stress pathways that underlie Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders. AMX0035, Amylyx’s lead program, has been shown in preclinical studies to protect neurons against death in a damage model by mitigating cellular stress and mitochondrial dysfunction. Following positive Phase 2 clinical results for ALS, AMX0035 is now being investigated in Phase 3 trials. Amylyx is also testing AMX0035 in patients with Alzheimer’s disease and Wolfram Syndrome.